Mirum Pharmaceuticals
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.0 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 114.86% +2.04pp
- Institutions
- 413 +6
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 11.76% |
| Christopher Peetz | Chief Executive Officer | 0.60% |
| Michael Grey | Independent Non-Executive Chairperson | 0.43% |
| Peter Radovich | Chief Operating Officer | 0.09% |
| Eric Bjerkholt | Chief Financial Officer | 0.07% |
| Joanne M. Quan | Former Chief Medical Officer | 0.03% |
| Jolanda Howe | Senior VP & Global Controller | 0.03% |
| Laura Brege | Independent Director | 0.02% |
| Laurent Fischer | Independent Director | 0.02% |
| Lon Cardon | Independent Director | 0.01% |
| Timothy Walbert | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Laura Brege | Independent Director | Derivative Exercise and Sale | -14,167 | $16.71–94.74 |
| 2026-11-03 | Joanne M. Quan | Former Chief Medical Officer | Intent to Sell (Form 144) | -14,684 | $96.97 |
| 2026-11-03 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–90.00 |
| 2026-10-15 | Jolanda Howe | Senior VP & Global Controller | Derivative Exercise and Retained | +16,112 | $19.24 |
| 2026-10-08 | Rob Myers | Chief Medical Officer | Other Derivative Acquisition | +25,000 | -- |
| 2026-10-08 | Rob Myers | Chief Medical Officer | Other Derivative Acquisition | +40,000 | $86.01 |
| 2026-10-05 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Retained | +12,197 | $15.87–19.19 |
| 2026-09-20 | Rob Myers | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Sale | -9,943 | $98.37 |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Intent to Sell (Form 144) | -9,943 | $98.37 |
| 2026-09-10 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Retained | +8,390 | -- |
| 2026-09-01 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -658 | $100.00 |
| 2026-08-31 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -30,000 | $2.94–98.91 |
| 2026-08-17 | Jolanda Howe | Senior VP & Global Controller | Derivative Exercise and Sale | -40,000 | $6.27–100.00 |
| 2026-08-10 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -6,001 | $99.90 |
| 2026-08-09 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–100.14 |
| 2026-08-02 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -1,840 | $105.29 |
| 2026-07-05 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -5,000 | $121.67–124.94 |
| 2026-07-05 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–124.79 |
| 2026-06-30 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -2,721 | $120.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Mirum Pharmaceuticals discussion 0 comments